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Abstract
Background: Classical approaches to predicting patient clinical outcome via gene expression information are
primarily based on differential expression of unrelated genes (single-gene approaches) or genes related by, for
example, biologic pathway or function (gene-sets). Recently, network-based approaches utilising interaction
information between genes have emerged. An open problem is whether such approaches add value to the
more traditional methods of signature modelling. We explored this question via comparison of the most widely
employed single-gene, gene-set, and network-based methods, using gene expression microarray data from two
different cancers: melanoma and ovarian. We considered two kinds of network approaches. The first of these
identifies informative genes using gene expression and network connectivity information combined, the latter
drawn from prior knowledge of protein-protein interactions. The second approach focuses on identification of
informative sub-networks (small networks of interacting proteins, again from prior knowledge networks). For all
methods we performed 100 rounds of 5-fold cross-validation under 3 different classifiers. For network-based
approaches, we considered two different protein-protein interaction networks. We quantified resulting patterns
of misclassification and discussed the relative value of each relative to ongoing development of prognostic
biomarkers.
Results: We found that single-gene, gene-set and network methods yielded similar error rates in melanoma and
ovarian cancer data. Crucially, however, our novel and detailed patient-level analyses revealed that the different
methods were correctly classifying alternate subsets of patients in each cohort. We also found that the network-
based NetRank feature selection method was the most stable.
Conclusions: Next-generation methods of gene expression signature modelling harness data from external
networks and are foreshadowed as a standard mode of analysis. But what do they add to traditional approaches?
Our findings indicate there is value in the way in which different subspaces of the patient sample are captured
differently among the various methods, highlighting the possibility of ‘combination’ classifiers capable of
identifying which patients will be more accurately classified by one particular method over another. We have seen
this clearly for the first time because of our in-depth analysis at the level of individual patients.
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Background
Gene expression signatures have long been heralded for
the way in which they might revolutionise clinical prac-
tice in terms of personalising medicine: a regime in
which clinicians have the ability to segment heteroge-
neous subsets of patients according to the treatment
options from which they are expected to derive the most
benefit [1]. However, despite some 15 years of rigorous
investigation across a multitude of cancer types there is a
worrying dearth in the translation of this particular class
of biomarker [2-5]. This situation presents a clear and
pressing opportunity for the critical examination and
ongoing development of methods to: 1) select clinically
relevant features from gene expression microarray infor-
mation; and, 2) use a quantitative measure of those fea-
tures to define a model which can be used to accurately
distinguish between groups of interest e.g., longer versus
shorter survival.
Identification of a prognostic gene expression signature
can be considered, in essence, a two-step procedure. First,
the informative features are identified, for example by
ranking all potential features in such a way that assigns
the top ranks to those that differ most between the groups
of interest. The top-ranked features are then selected for
classification, which is the second step in the signature
building process. The classifier itself is an algorithm - or a
function of several variables or features - that can be
mapped to a categorical space, such as the binary space
consisting of longer (good prognosis, GP) or shorter (poor
prognosis, PP) survival after diagnosis with cancer, as we
explore herein.
The most widely used methods in gene expression sig-
nature modelling to date can be partitioned into two
broad groups [6]. The first of these approaches is the
‘single-gene’ method in which no prior or external infor-
mation is incorporated into the analysis in any way. The
features for these methods are individual genes identi-
fied, for example, via differential expression analysis
(Figure 1A). In the classification step of the single-gene
approach, a classifier is built which takes the expression
values of these informative genes as the input, and out-
puts the predicted class of the sample. The second gen-
eral approach, termed the ‘gene-set’ method, involves
grouping genes together into sets to be used as classifi-
cation features. Such genes are typically related via co-
membership of a biochemical pathway or other biologic
feature. The classification features for gene-set methods
are usually the sets of genes themselves that are consid-
ered to differ between the groups of interest in some
way (Figure 1B). In this case a measure that can quantify
a gene-set independently for each sample, analogous to
the way in which single genes are quantified by their
expression values, is needed. For clarity we note that
gene-set approaches are often referred to as pathway
methods and sometimes, confusingly, as network meth-
ods. However the distinction between gene-set methods
and network methods in this study is that gene-set
methods do not incorporate any network edge informa-
tion (vide infra) into the feature selection procedure or
the feature values.
In recent years, network-based methods of gene
expression analysis have grown in popularity for their
capacity to capture or explain emergent properties such
as biological heterogeneity, modularity, or phenotypic
variability [7]. A network, or a graph as it is known in a
mathematical context, consists of a set of nodes, V, and
a set of edges, E, between the nodes. A network can be
described by an adjacency matrix W = (wij), in which a
non-diagonal entry, wij is the number of edges from
node i to node j (equal to zero if no such edge exists).
The degree of a node is defined to be the number of
edges incident to the node and a hub is a highly con-
nected node which we defined as node with at least 5
interactors in the network, consistent with the definition
of a hub in prior related works [8-10]. A sub-network is
a network whose vertex set is a subset of V and whose
edge set is a subset of E restricted to this vertex set i.e.,
a smaller portion of the entire known network. A hub
sub-network is a sub-network consisting of a hub node
and its immediate interactors together with the hub-
interactor edges. The concept of a network is easily
translated into a biological setting with genes repre-
sented by nodes and relationships between genes (such
as interactions) represented by edges (Figure 1C). In this
study we examine protein-protein interaction (PPI) net-
works in which nodes correspond to protein-coding
genes (representing the mRNA information) and the
existence of an edge between two such genes implies
that the proteins coded for by those genes interact in a
direct and physical manner with each other in a biologi-
cal setting.
A number of approaches exist involving the utilisation
of PPI networks in gene expression signature modelling
[7]. We examine two increasingly popular strategies
herein [8]. The first approach [11] focuses on the net-
work properties of individual genes. More specifically,
individual genes are used as the classification features
while the PPI network information is used in feature
selection to identify the most informative genes. This is
in contrast to the (non-network) single-gene method
introduced above in which the classification features are
individual genes, but with no utilisation of network
information. The second network-based method focus-
ing on informative sub-networks (rather than individual
genes) is a particularly active area of investigation
[8,10,12]. This approach involves mathematical integra-
tion of PPIs with gene expression information to identify
differential network behaviour such as changes in
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correlation between the gene expression profiles of
interacting gene pairs (Figure 1C). In this approach, the
feature selection process involves identifying informative
sub-networks such as those whose correlation structure
differs between the groups of interest. The sub-networks
examined in this study are of the hub-type described
above. The classification features for this type of net-
work approach are then defined as the informative hub
sub-networks themselves or are extracted from them
e.g., by considering the edges or the hub genes within
the hub sub-network.
In this study we evaluated and compared the three fun-
damental kinds (single-gene, gene-set, and network-
based) of gene expression biomarker modelling described
above (also summarised below and in Table 1). Specifi-
cally, we explored their capacity to classify tumors
according to phenotypes of distinct pathophysiological
states and associated clinical outcomes in previously
well-characterised melanoma [13,14] and ovarian cancer
[15] cohorts. For statistical rigour, we employed three
different classifiers each under 5-fold cross-validation
scenarios: random forest (RF) [16], diagonal linear discri-
minant analysis (DLDA) [17] and support vector
machines (SVMs) [18].
Overall we aimed to critically evaluate the relative
contribution of PPI network-based approaches (cf. the
now classical single-gene and gene-set methods) to gene
expression signature profiling in cancer prognostication.
Figure 1 Examples of informative features which differ between the PP class (red) and GP class (blue). These examples were obtained
using the melanoma data set and the iRefWeb network. A) presents the differential expression of the TRAF3 gene (the x-axis corresponds to the
samples and the y-axis corresponds to the expression values), B) presents the differential (median) expression of the CD19 gene-set which
consists of 6 genes (the x-axis corresponds to the samples and the y-axis corresponds to the expression values), and C) presents the differential
correlation of the DTX1 hub sub-network (for visual simplicity, we present the hub gene expression (x-axis) versus interactor gene expression (y-
axis) for three of the five edges in the DTX1 hub sub-network and for 10 samples from each class). The hub-interactor correlations for each hub-
interactor pair are presented. Image adapted from [6].
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What was novel in our analytical approach, beyond eva-
luation of overall classification error rates and feature
selection stability, was the modelling of findings both at
the class-specific level and at the level of individual
patients. The former process involved observing the
average error rates over the poor prognosis samples and
the good prognosis samples, while the latter analysis
considered the proportion of cross-validation folds in
which each patient was correctly classified. Via this
unique approach, we made a number of observations.
First, consistent with the findings of [19-21], the overall
classification error rates across the single-gene, gene-set
and network methods were comparable, suggesting that
more complex models when assessed purely by classifi-
cation error rates aren’t necessarily more accurate. Sec-
ond, we found that one particular network-based
approach - NetRank [11] - was considerably more stable
with respect to all other methods evaluated herein. This
finding is in contrast with prior literature [19,20] in
which network-based methods did not show an increase
in stability cf. single-gene methods. It implies that incor-
poration of network information may lead to the identi-
fication of more stable gene expression signatures.
Finally, by considering our results at the level of indivi-
dual patients, we observed that different methods were
capturing different subsets of the sample space i.e., the
different approaches were correctly classifying different
samples. This finding has the implication that there may
in fact be a sub-class of patients who are more accu-
rately classified by single-gene methods cf. network-
based or gene-set methods and vice-versa. As a result, a
possible future direction of research in this area could
be the development of a combination classifier capable
of identifying which patients will be more accurately
classified by one particular type of method over the
other.
For clarity we begin with a précis and motivation for
the selection of each of the approaches evaluated in this
study.
Single-gene methods - a historical overview
The first methods to arise dealing with gene expression
signatures were single-gene methods based on identifi-
cation of individual differentially expressed (DE) genes.
One initial and extremely simple approach to DE analy-
sis was to calculate the gene expression fold-change
[22-24], and define DE genes as those genes for which
expression values exhibited the largest fold-change
between two groups of interest. The next approach to
DE analysis was to employ the t-test to identify genes
having differential expression between groups of interest
[25]. A standard t-test, however, did not adjust for indi-
vidual gene variability. To counter this issue, modifica-
tions of the standard t-test were introduced [26]. Other
statistical tests continued to arise for use on microarray
data, including but not limited to ANOVA [27] and
RVM [28]. However, the two most prominent single-
gene methods to arise have been: 1) the significance
analysis of microarrays (SAM) [29], which performs a
non-parametric permutation-based test that does not
assume equal variance of the genes; and, 2) the moder-
ated t-statistic method (implemented by the limma
package in R [30]), for which a robust linear model is fit
to the expression profile for each gene. The moderated
t-tests performed based on these models have increased
degrees of freedom and the standard errors are moder-
ated across the genes using a Bayesian model. The mod-
erated t-statistic method is often considered to be the
preferred method of differential gene expression analysis
[31] and is thus the main single-gene method evaluated
herein (Table 1 Figure 1A).
Gene-set methods - the increasing sophistication of
signature modelling
In the years following the rapid growth of the single-gene
methods, approaches that considered sets of genes rather
than individual genes began to emerge. Below we describe
a few of the commonly used differential gene-set (or path-
way) methods. The first of these approaches was gene set










Mod-t Rank genes by p-value Single gene Expression value Yes Smyth et al. [30]
Gene-set Median
expression
Rank gene-sets by p-value Gene-set Median expression value of all genes in
the gene-set
No
Network NetRank Rank genes using NetRank
algorithm
Single gene Expression value Yes Winter et al. [11]




Expression difference between hub and
interactor gene connected by the edge
Yes Taylor et al. [8]




Expression value of the gene No
Description of the methods assessed in terms of the way in which external information is incorporated, the feature selection procedure, the features used for
classification, and a reference if the method is obtained from a previous publication.
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enrichment analysis (GSEA) , [32] for which an enrich-
ment score is calculated for each gene-set reflecting the
extent to which the gene-set is overrepresented at the
extremes of the ranked list of DE genes. This method is
based on the Wilcoxon rank sum test and there are a large
number of variations including non-parametric methods
such as gene set enrichment analysis rotation (GSEArot)
[33], gene set analysis (GSA) [34]. Parametric methods
include the random set method [35] and generally applic-
able gene set enrichment (GAGE) [36]. These gene-set
methods are all examples of ‘competitive gene-set meth-
ods’ that utilize data not only from the gene-set of interest,
but also data from outside the gene-set of interest.
Another approach employs a modified multivariate Hotell-
ing’s T2 test method [37] analogous to the single-gene uni-
variate t-test approach. More recently, [38] described an
algorithm, Pathifier, which uses expression data to calcu-
late pathway deregulation scores.
It is important to note that the above methods offer an
insight into the huge number of existing ways to identify
informative or significant gene-sets but offer no means of
translating these significant features into a classification
setting. In particular, to use gene-sets as classification
features, we must have a measure which can be used to
quantify them independently for each sample in a man-
ner analogous to the way in which individual genes are
quantified by their expression values. The most obvious
gene-set measure is to take the median expression of the
genes within the set, which we will use herein. In the
interests of using a feature selection procedure for which
the median-expression measure will be able to capture
the difference between the groups of interest, we utilised
a gene-set analog of the single-gene moderated t-statistic
method (Table 1 Figure 1B).
Network approaches - a new class of tests
Although there are several methods that claim to be net-
work methods in the literature [39,40], closer examination
of several such methods reveal that they in fact fall into
the category of gene-set methods since no network edge-
information is utilized. Specifically, the majority of
network-based methods focus on estimating network
information from gene-expression data using probabilistic
analyses, such as clustering, to infer co-regulated genes
from co-expressed genes [41]. Recently, the weighted gene
co-expression network analysis (WGCNA) approach [42]
incorporated information corresponding to patient survi-
val with their data-derived network. In this study we take
a different approach by examining predefined networks,
where we focus instead on incorporation of external PPI
information. As stated above, we concentrate on two
kinds of network approach; the first approach (which
focuses on the network properties of individual genes) is
one wherein individual genes are used as the classification
features while PPI network information is incorporated
into the feature selection procedure (Table 1). The pri-
mary network-based method of this type considered in
this study is the NetRank algorithm [11]. NetRank is based
on Google’s PageRank algorithm which works by estimat-
ing the importance of a website by counting the number
of links to it. However, NetRank is not the first method to
attempt to replicate the PageRank algorithm in a genomic
setting; [43] described an algorithm called GeneRank
based on a similar idea. These algorithms estimate the
relevance of a gene to the phenotype or ‘class of interest’
through consideration of both network connectivity and
the gene’s expression profile. There are several other
examples of network methods of this type including the
method described by [44] based on random walks, which
utilises prior information on the relative importance of
each gene. Another example is the CIPHER algorithm [45]
which identifies disease genes by considering phenotypi-
cally similar diseases and a complete list of known disease
gene-phenotype associations. A third example is the work
of [46], aiming to measure the importance of genes by
maximizing a likelihood function and identifying those
genes that are the most highly connected. We note, how-
ever, that the above examples either focus on a different
network-type [46] or require extra external information
[44,45] and are therefore not evaluated in this study. In an
example of the second type of network approach (which
focuses on the properties of sub-networks, rather than
individual genes), [8] identified sub-networks having a cor-
relation structure that differed between conditions. The
authors also offered a means of translating this feature
selection method into a classification framework by using
the edges from the differentially correlated networks as
the classification features (Table 1 Figure 1C). We further
adapted this idea of identifying differentially correlated
networks by considering those with a large between-to-
within sum of squares (BSS/WSS) ratio for the correlation
values over the groups of interest. Other network
approaches that focus on the identification of differential
sub-networks include the method described by [47] which
is based on the spectral decomposition of the gene expres-
sion profiles with respect to the eigen functions of the net-
work. Similarly, [48] described an entropy-based method
focusing on measuring the effect of randomness of single-
genes while [49] proposed a different entropy-based
method focusing on analysis of a heat kernel stochastic
matrix. Unfortunately, the sub-network measures
employed in these approaches are somewhat uninformative
when applied to the structurally simple hub sub-networks
as opposed to more complex sub-network structures.
Therefore, in this study we look only at the network
approach of [8] as well as the adapted BSS/WSS measure.
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Methods
Gene expression microarray data sets
The melanoma microarray data set from [13] contains
expression data for 17,552 genes for each of 47
patients with metastatic (stage III) melanoma, follow-
ing filtering and processing as described in [13]. We
previously [13] analysed the distribution of survival
times to identify patients with more favourable (GP)
and less favourable (PP) prognosis. These groups were
defined as having time from surgery to death from
melanoma greater than 4 years with no sign of relapse
or less than one year. The data set contains 25 good
prognosis samples and 22 poor prognosis samples
(ngood_prognosis_melanoma=25:npoor_prognosis_melanoma=22).
In addition to the melanoma data set we used the ovar-
ian cancer data previously reported in [15] that describes
a series of patients with stage III, high-grade primary
papillary serous tumors of the ovary. We defined the
poor prognosis class as patients who died within 2 years
after surgery and the good prognosis class as patients
alive more than 3 years after surgery. Following proces-
sing and filtering (per [15]), the data set consisted of
expression data for 12,981 genes for each of 72 samples
(ngood_prognosis_ovarian=33:npoor_prognosis_ovarian=39).
Protein-protein interaction (PPI) networks
We examined two previously analysed [10] PPI networks
obtained from the MetaCore™ (from GeneGO™ Inc.,
version 6.6, build 28323) and iRefWeb (V3.4, March 2,
2011) [50] databases respectively. The MetaCore™ net-
work contains 5,009 genes (4,069 of which appear in the
melanoma microarray data set) and has 16,202 edges.
The iRefWeb network comprises 7,256 genes (5,981 of
which appear in the melanoma microarray data set and
5,623 of which appear in the ovarian cancer data set)
and has 21,049 edges. Consistent with prior related lit-
erature [8], we defined a hub gene to be a gene with
degree greater than or equal to 5 and a hub sub-net-
work as the sub-network generated by considering a
hub gene and its immediate interactors.
Statistical analyses of single-gene, gene-set, and network-
based methods
Comparison study - overall strategy: We evaluated and
compared various single-gene, gene-set and network-
based methods (Table 1). For each method, we first per-
formed a feature selection step to identify informative
explanatory variables or ‘features’. These features were
then used to build a model or ‘classifier’. For all methods,
the values used to quantify the classification features
were calculated independently for each sample. Specifi-
cally, although values drawing information from more
than one sample, such as by calculating correlation or
p-values, can be used to perform feature selection, they
cannot be used to define feature values for classification.
We compare three different classifiers: 1) a tree-based RF
classifier implemented using the randomForest package
[16]; 2) an SVM classifier implemented using the e1071
package [51]; and, 3) a DLDA classifier implemented
using the supclust package [52] in R [53]. For statistical
rigour, all classification error rates were estimated using
100 rounds of 5-fold CV [53]. The mathematical details
of the single-gene, gene-set and network methods per-
formed in this study are given in Additional File 1 (Sup-
plementary methods). However, for clarity we offer a
brief description of each below.
Comparison study - single-gene approach: The sin-
gle-gene method used was the moderated t-statistic,
implemented via the lmFit and eBayes functions from the
limma package [30] in R [53]. Briefly, we performed fea-
ture selection using a robust linear model that was fitted
to the expression profile for each gene. To identify the
most differentially expressed genes, moderated t-tests
were performed based on these models. The moderated
t-test had increased degrees of freedom and the standard
errors were moderated across the genes using a Bayesian
model [30] (Additional File 1 - Supplementary methods:
Single-gene approaches - moderated t-statistic).
Comparison study - gene-set approach: The gene-set
method analysed was the median expression approach in
which gene-sets were quantified by the median expression
of the genes contained within the set (inspired by the aver-
age expression measure described by [39] and work by
[30]). The moderated t-statistic method was then applied
to the gene-sets rather than the individual genes. That is, a
robust linear model was fitted to each gene-set and mod-
erated t-tests were performed to identify the most DE
gene-sets. The gene-sets considered to be the most DE
were then used as the classification features with the fea-
ture value defined to be their median expression value. In
this study we used the PPI network information described
above to define the gene-sets. In particular, gene-sets were
defined as the sets of genes appearing together in a hub
sub-network i.e., each gene-set contained a hub gene (a
gene with at least 5 incident edges) and its immediate
interactors (PPI partners). The network edges were
ignored (Additional File 1 - Supplementary methods:
Gene-set approaches - median expression).
Comparison study - network-based approaches: We
undertook three network methods. The first of these,
NetRank [11], is based on individual genes with the net-
work information incorporated in the feature selection
procedure. The NetRank algorithm iteratively assigned a
rank to each gene, which depended both on the rank of
all genes connected to it via an edge in the network and
on the correlation of the gene’s expression profile with
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survival time. The extent to which the network influ-
enced the rank of each gene was determined by the
value of a parameter a (Additional File 1 - Supplemen-
tary methods: Network-based feature selection methods
focusing on the network properties of individual genes -
NetRank).
We next considered the method by [8] (referred to for
clarity herein as Taylor’s method) based on identifying
differential network behaviour within sub-networks. To
perform feature selection the average difference in corre-
lation (calculated for each edge in a network by consider-
ing the expression profiles of the protein-pair joined by
the edge) for each hub sub-network over the two groups
of interest was calculated. This calculation offered a mea-
sure of differential correlation for each hub sub-network
which was used to select the most differentially corre-
lated hub sub-networks. The edges from the most differ-
entially correlated hub sub-networks were then used as
the classification features and each edge was quantified
by the expression difference between the hub gene and
interactor gene joined by the edge (Additional File 1 -
Supplementary methods: Network-based feature selection
methods focusing on sub-networks - Taylor’s approach
and BSS/WSS).
Finally, we used the BSS/WSS approach, inspired by
Taylor’s differential correlation measure. However,
instead of calculating the difference in correlation
between the two prognostic groups of interest, we calcu-
lated the BSS/WSS ratio for the correlation values over
those groups. This ratio was then used to rank the hub
sub-networks from most to least differentially correlated
and the hub genes from the hub sub-networks consid-
ered to be the most differentially correlated were then
used as the classification features (Additional File 1 -
Supplementary methods: Sub-network-based feature
selection methods for the network approach - Taylor’s
approach and BSS/WSS).
Evaluation criterion1 - stability: We evaluated the
stability of each feature selection method - single-gene,
gene-set, and network-based - by considering the average
number of selected features that were common to each
pair of the 500 cross-validation (CV) folds (correspond-
ing to the 100 rounds of 5-fold CV). We examined the
average stability for each method when selecting the top
20, 30, 40 and 50 features in each of the CV folds.
Evaluation criterion 2 - error estimation under 5-fold
cross-validation: For all models we performed 5-fold CV
[54] i.e., splitting the data into five equal subsets (or as
equal as possible). Here, one subset (referred to as the test
set) was withheld for testing purposes while the remaining
samples were used to train the classifier. The withheld
subset was then used to estimate an error rate for the clas-
sifier. This procedure was repeated using each subset as
the test set to obtain a total of five error rates. The 5-fold
CV error rate was then defined to be the average of these
five error rates. The final error rate estimate was defined
to be the average 5-fold CV error rate over 100 rounds
(Additional File 2 - Supplementary Figure 1).
Evaluation criteria 3 - accuracy analysis at a patient-
level: To perform a detailed comparison of the relative
performance of each method considered, we scrutinized
the classification accuracy achieved for each individual
patient. In each fold of the 5-fold CV procedure, the class
of each sample in the test set was predicted. Since each
sample appeared in the test set exactly once per round of
5-fold CV, we had exactly one class prediction for each
patient following each round. Thus, we calculated patient-
specific classification error rates by identifying the propor-
tion of CV rounds in which the patient was misclassified
(see Figure 5 legend for additional details).
Results
A comparison of single-gene, gene-set and network
methods in melanoma identified NetRank as the most
accurate method among them
For each method evaluated (Table 1), error rates were
estimated using 100 rounds of 5-fold cross-validation for
each of the RF, SVM, and DLDA classifiers. The 5-fold
CV error rates achieved by the single-gene, gene-set and
network methods for the melanoma data set and the
iRefWeb network using the RF, SVM, and DLDA classi-
fiers respectively, were: 31% (RF), 39% (SVM), and 33%
(DLDA) for the single-gene moderated t-statistic method;
35% (RF), 37% (SVM), and 37% (DLDA) for the gene-set
median expression method; 33% (RF), 29% (SVM), and
29% (DLDA) for the NetRank network-based method;
39% (RF), 38% (SVM), and 39% (DLDA) for Taylor’s net-
work method; and, 39% (RF), 45% (SVM), and 41%
(DLDA) for the BSS/WSS network method (Figure 2A).
The network-based NetRank method was thus the most
accurate method, achieving the lowest error rates. This
was followed by the single-gene moderated t-statistic
method which performed similarly for the RF and DLDA
classifiers but much poorer for the SVM classifier and,
achieved an error rate that was 10% higher than that for
NetRank. The gene-set median expression method per-
formed slightly better than Taylor’s network method,
which was comparable to the single-gene moderated t-
statistic method for the SVM classifier, but was much
less accurate for the RF and DLDA classifiers.
The same comparison of methods using ovarian cancer
data did not confirm the relative accuracy of the NetRank
approach
For the ovarian cancer data set, 5-fold CV error rates
achieved by the single-gene, gene-set and network meth-
ods using the iRefWeb network and the RF, SVM and
DLDA classifiers respectively, were: 35% (RF), 32%
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(SVM), and 37% (DLDA) for the single-gene moderated
t-statistic method; 40% (RF), 42% (SVM), and 41%
(DLDA) for the gene-set median expression method;
41% (RF), 43% (SVM), and 45% (DLDA) for the
NetRank network-based method; 36% (RF), 36% (SVM),
and 39% (DLDA) for Taylor’s network method; and 42%
(RF), 42% (SVM), and 43% (DLDA) for the BSS/WSS
network method (Figure 2B). Compared with the obser-
vations made in melanoma above, the error rates for the
ovarian cancer data were slightly higher and the
NetRank network method no longer appeared to be the
most accurate method. Instead, the single-gene moder-
ated t-statistic methods performed best followed closely
by Taylor’s network method. The median expression
gene-set method performed similarly to the BSS/WSS
network method whereas the median expression gene-
set method was more accurate than the BSS/WSS net-
work method for the melanoma data set.
Comparative analyses of within-class error revealed that
the different classes achieved different error rates
An evaluation of the class-specific (good versus poor
prognosis) error rates for each of the methods revealed
that patients with good prognosis were easier to classify
than patients with poor prognosis in the melanoma data
set (Figure 3A). Specifically, for the RF classifier error
Figure 2 Classification error rates. The error rates (y-axis) obtained from 100 rounds of 5-fold cross validation are presented for the RF
classifier, the SVM classifier and the DLDA classifier for iRefWeb network and A) the melanoma data set and B) the ovarian cancer data set. The
numbers within the parentheses following the method names are the number of selected features in each cross-validation round.
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rates for all methods ranged from 34-47% for the PP
class and from 25-32% for the GP class. Under SVM
classification, error rates ranged from 36-58% for the PP
class and from 21-32% for the GP class. Using the
DLDA classifier, error rates ranged from 29-51% for the
PP class and from 26-34% for the GP class. The only
exception to this observation was in case of the single-
gene moderated t-statistic and NetRank methods under
the DLDA classifier in which the PP class and the GP
class had similar classification error rates.
Similarly, error rates varied among survival classes in
the ovarian cancer data. However, in these data, lower
average error rates were observed for patients classified
as PP (Figure 3B). For the RF classifier, the PP class
achieved average error rates ranging from 21-33%, while
the GP class achieved error rates ranging from 44-57%.
For the SVM classifier, the PP class achieved error rates
ranging from 25-38% and the GP class achieved error
rates ranging from 39-60%. Finally, for the DLDA classi-
fier, the PP class achieved error rates ranging from 33-
47% and the GP class achieved error rates ranging from
41-48%. The difference in error rate between the PP
class and the GP class was notably less extreme for the
DLDA classifier.
Figure 3 Class-specific classification error rates. The GP (dotted line) and PP (solid line) error rates averaged over the 100 rounds of 5-fold
cross validation for each method are presented for the iRefWeb network and the RF classifier, the SVM classifier and the DLDA classifier using A)
the melanoma data set and B) the ovarian cancer data set.
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Comparative assessment of feature stability among
single-gene, gene-set, and network-based approaches:
NetRank performed best
The stability of the network-based NetRank method
exceeded the stability of all other methods, with an aver-
age of 63% of features in common for the CV fold pairs
when considering the top 50 features (Figure 4A). In
this respect it out-performed the single-gene moderated
t-statistic method which had very similar stability to
Taylor’s network-based method. NetRank was also more
stable than the median-expression gene-set method.
These methods each had an average of 38% of features
in common for their CV fold pairs when considering
the top 50 features. The BSS/WSS network-based
method was the least stable with an average of only 9%
of features in common among the CV fold pairs when
considering the top 50 features. The relative stability of
each feature selection method observed in the mela-
noma data set was comparable to those observed using
the ovarian data (Figure 4B).
Single-gene, gene-set, and network-based methods
captured different subspaces of the cohorts evaluated
We undertook a novel comparison of the single-gene,
gene-set, and network-based approaches at the level of
individual patients (Figure 5A, Additional Files 345). Over-
all, 10-15 samples in the melanoma dataset (depending on
which classifier was used) were almost always classified
correctly by every method. We refer to these henceforth
as samples being ‘easy to classify’. 7-9 samples (again,
dependent on the classification algorithm) were almost
never classified correctly by any method. Conversely, we
refer to these samples as being ‘hard to classify’. The
remaining samples were better classified by some methods
than by others.
Overall, the network-based NetRank method and the sin-
gle-gene moderated t-statistic method performed similarly
at the level of individual samples. In particular, they per-
formed better than the gene-set median expression
method, the BSS/WSS method, and Taylor’s approach. We
noticed that for the 10-14 PP samples which were very
accurately classified by the single-gene moderated t-statistic
method and the NetRank network-based method, the med-
ian expression gene-set and remaining network methods
were much less accurate in classifying all but 3 of these
samples. On the other hand, there were approximately 2-6
GP and 2-3 PP samples (depending on which classifier is
used) which were more accurately classified by these gene-
set and network methods cf. the single-gene moderated
t-statistic method and the NetRank network-based method.
In sum, the single-gene moderated t-statistic method and
the NetRank network-based method captured a different
subspace of the samples relative to the median expression
gene-set method, Taylor’s network method and the BSS/
WSS network approach.
For the ovarian cancer data set, we observed 13-17
samples (classifier-dependent) that were almost always
classified correctly by every method. Similarly, 9-11
samples were almost never classified correctly by any
method (Figure 5B, Additional Files 678). Although the
NetRank network method and the single-gene moder-
ated t-statistic method appeared to perform similarly at
Figure 4 Stability of the feature selection methods. The number of selected features pair-wise in common over the 100 rounds of 5-fold
cross-validation (thus over a total of 500 selected feature lists) for each of the single-gene, gene-set and network methods based on the
iRefWeb PPI network for A) the melanoma data set and B) the ovarian cancer data set, with respect to the number of features selected.
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the patient level for melanoma, this trend was not
observed in ovarian cancer. Nonetheless, gene-set and
network methods continued to capture different subsets
of the sample space cf. the single-gene moderated t-sta-
tistic method. For example, the gene-set median expres-
sion method less accurately classified 8-9 samples but
more accurately classified 5-7 samples. In contrast,
NetRank less accurately classified 11-17 samples cf. the
single-gene method but more accurately classified 4-11
samples. In addition, Taylor’s method less accurately
classified 7-9 samples compared with the single-gene
method while more accurately classifying 7 samples.
BSS/WSS less accurately captured 13-20 samples cf. the
single-gene method and more accurately classified 1-4
samples.
Observations relating to network-methods were validated
using an independent PPI network
When we repeated the analysis in melanoma using the
MetaCore™ PPI network in place of the iRefWeb PPI
network the same general patterns were observed (Addi-
tional File 9: Supplementary results). That is: 1) the sin-
gle-gene moderated t-statistic method and the network-
based NetRank method performed slightly better in
terms of classification error rate than the remaining
methods (Additional File 10: Supplementary Figure 2);
2) the samples in the GP class were classified more
accurately than the samples in the PP class (Additional
File 11: Supplementary Figure 3); 3) NetRank was the
most stable feature selection method cf. BSS/WSS which
was the least stable while the remaining methods all
Figure 5 Classification accuracy at the patient level. A black cell corresponds to the patient being classified correctly in all 100 CV rounds,
whereas a white cell corresponds to the patient being classified correctly in none of the 100 CV rounds for the RF classifier, the SVM classifier
and the DLDA classifier using A) the melanoma data set and B) the ovarian cancer data set, together with the iRefWeb PPI network. The rows
are split into single-gene (the first row), gene-set (the second row) and network-based method (the last three rows). The tumor IDs are given on
the x-axis, and the average error rate (taken over the 100 rounds of CV) are provided on the right-hand-side y-axis.
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displayed similar stability (Additional File 12: Supple-
mentary Figure 4); and, 4) the various methods evalu-
ated captured different subspaces of the sample space
(Additional File 13: Supplementary Figure 5, Additional
Files 141516: Supplementary Tables 7-9).
Discussion:
Development of accurate prognostic gene expression
signatures is a central challenge in clinical cancer
research. We aimed to analyse and compare commonly
employed single-gene and gene-set methods for prog-
nostic classification alongside the more recent network-
based approaches involving integration of PPI networks
with gene expression information [8,11]. To focus our
research on the potential value of these newer PPI net-
work-based methods we excluded methods requiring
additional information beyond a priori PPI knowledge.
For the same reason, we also limited our comparison to
the gene-set approach (median expression, [30,39])
which is a direct analog of the single-gene moderated-t
statistic method [30] also considered herein. Moreover,
and for the first time, we conducted an analysis at the
level of individual patients as well as with respect to the
classes being compared (good versus poor prognosis).
We undertook our analyses using gene expression
microarray information from two previously reported
studies in separate cancers (melanoma [13] and ovarian
[15]) and utilised PPI information from two different
networks (MetaCore™ and iRefWeb [50]). Each of the
methods analysed comprised a feature-selection algo-
rithm which was followed by classification in R [53]
using each of three different classifiers: RF, SVM and
DLDA. All classification error rates were estimated
using 100 rounds of 5-fold CV [54].
Single-gene, gene-set, and network-based methods
achieved similar error-rates, confirming prior observations
and emphasizing questions about their value
Our first finding - that the different approaches achieved
similar error rates with respect to each other - validates
prior observations by [19-21]. Specifically, none of the
classifiers employing composite features derived from
secondary PPI data sources (the network-based
approaches) out-performed the classical single-gene/
gene-set approaches. We also observed that their perfor-
mance in terms of error-rates varyied with the cancer
data set being analysed. For example, NetRank achieved
the lowest error rates overall in the melanoma cohort, a
finding that did not hold up using the ovarian cancer
data set but which was consistent with the findings of
[55] who noted that of the 25 datasets they analysed,
NetRank outperformed a number of classical single-gene
methods in 23 of them.
Patient-level analyses indicated there is value to be
gained from network-based methods
Prior related reports have described and discussed the
single-gene, gene-set, and network-based approaches to
gene expression signature modelling to varying degrees
[6,56]. However, these works did not analyse first hand
nor consider in detail the methods for translation of such
feature selection methods into a general classification
framework. Of the previous studies that did undertake
formal evaluations, the focus has been upon network-
and pathway-based classifiers for outcome prediction in
breast cancers [19-21] or on comparing the effect of
using different kinds of external biological information in
the learning process like functional annotations, PPIs,
and expression correlation among genes [57]. Further,
these previous studies draw their conclusions based pri-
marily on classification error rates, whereas a particular
novelty of this study is that we considered (for the first
time) our results at the more in-depth level of individual
patients. Within this framework, we observed that differ-
ent methods were capturing different subsets of the sam-
ple space i.e., the different approaches were correctly
classifying different samples. These results would suggest
that new composite classification methods are needed to
capture the complementary value of network-based,
gene-set and classical single-gene approaches.
Analyses of error rates within the good and poor survival
classes further highlights the need for a composite
approach to gene expression signature modelling
Our finding that samples from the GP class were easier
to classify in melanoma, but samples from the PP class
were easier to classify in ovarian cancer, highlights an
underlying dataset dependency of these gene-set and
network approaches. We also note some overall differ-
ences between the datasets. Performing a moderated
t-statistic differential expression analysis on each data
set (Additional File 9 - Supplementary results: Compari-
son of the ovarian cancer data set and the melanoma
data set), we found that the melanoma data set con-
tained 96 DE genes (p-value < 0.1) while the ovarian
cancer data set had only 13 DE genes. This observation
could offer an explanation as to why the methods focus-
ing on identification of individual informative genes (the
single-gene moderated t-statistic method and the
NetRank network method) perform better on the mela-
noma data set than in the ovarian cancer data. Further-
more, there was no overlap between the 100 most DE
genes from each data set. Using Taylor’s differential cor-
relation measure, and an arbitrary threshold of 0.5, we
found that the melanoma data set contained 23 differen-
tially correlation hub sub-networks and the ovarian can-
cer data set contained only 7. Thus in general it seems
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as though the melanoma data set contained more differ-
ential features between the PP and GP classes than the
ovarian data set, which could explain the lower error
rates obtained for melanoma.
NetRank is the most stable approach, supporting the
potential value of network-based approaches to
prognostication
Our assessment of the stability of features identified in
each method highlighted NetRank [11] as the most stable
approach in both cancers. This finding is consistent with
observations made by [55] who found that cancer-related
signatures identified by NetRank had significant overlap
between the data sets they considered. The study also
showed that performing classification on datasets with
the aim of classification into prognostic classes (as was
the goal here) was notably less accurate than when the
aim was to address diagnosis or sub-typing classification
problems,. This finding again confirms that incorporation
of network information may lead to identification of
more stable gene expression signatures.
Findings were validated in an independent PPI network,
suggesting network invariance of the network methods
Our reproduction of findings obtained using the iRef-
Web PPI network but instead using the MetaCore™
PPI network demonstrates that the network methods
are not hugely dependent on the PPI network used.
Strengthening this claim we note also that although the
two networks contain many of the same proteins, they
are somewhat different from one another in terms of
global structure (Additional File 9 - Supplementary
Results: Comparison of the MetaCore™ and iRefWeb
PPI networks).
Ongoing network issues
Network-based approaches continue to have important
limitations of consequence to their translational rele-
vance. In a PPI network, nodes correspond to protein-
coding genes, and the existence of an edge between two
such genes implies that the proteins coded for by those
genes interact in a biological setting. One of the most
significant issues in PPI network analysis is the inaccu-
racy and the lack of reliability of the available networks.
It has been noted that of the huge number of currently
available networks, there is very little overlap and con-
sistency between them [58-61]. Currently, the two main
approaches for identification of protein-protein interac-
tions are the yeast two-hybrid (Y2H) and the affinity
purification of complexes followed by mass spectrometry
(AP-MS). Details on these methods can be found in
[62]. Moreover, despite the huge number of publicly
and privately available PPI databases, there is no interac-
tion database covering the entire human genome.
However, there are ongoing projects, such as the
Human Interactome Project [63], with the aim of devel-
oping a complete human PPI map. Although our study
showed that the network methods are not hugely depen-
dent on the PPI network used, full elucidation of the
extent to which the a priori information impacts the
findings remains an open question.
Conclusions
The contextualisation of high-throughput data sets using
large-scale molecular interaction networks is emerging
as an increasingly popular bioinformatics approach for
the analysis of complex disease. Accurate prognostic
information is essential for clinicians to be able to reli-
ably stratify patients for a comparative assessment of
therapeutic interventions. But what, if anything, do
these next-generation methods add to traditional single-
gene and gene-set approaches? Our comparative analysis
reiterated that when assessed by error rates alone no
single approach reliably out-performed any other. How-
ever, for the first time, we show that the different meth-
ods - single-gene, gene-set, and network-based - are
correctly capturing different areas of the sample space.
These findings imply that network approaches do indeed
have the potential to enhance existing methods; we
posit, for example, through development of ‘combina-
tion’-type classifiers that are capable of identifying the
subset of patients for whom one approach may be more
accurate compared with another.
Availability of supporting data
The data sets supporting the results of this article are
available in the Gene Expression Omnibus (GEO) repo-
sitory: GSE53118 for melanoma [13] and GSE26712 for
ovarian cancer [15].
Additional material
Additional File 1: Supplementary methods. Mathematical descriptions of
the methods including the single-gene moderated t-statistic approach,
the median expression gene-set approach, the network-based NetRank
approach, Taylor’s network-based approach and the BSS/WSS network-
based approach.
Additional File 2: Supplementary Figure 1. A flow chart showing the
general method for performing 5-fold cross-validation.
Additional File 3: Supplementary Table 1. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the melanoma dataset with the
iRefWeb PPI and the RF classifier. The samples are identified by their
Tumour IDs. The order of the samples are the same as presented in
Figure 5A) RF.
Additional File 4: Supplementary Table 2. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the melanoma dataset with the
iRefWeb PPI and the SVM classifier. The samples are identified by their
Tumour IDs. The order of the samples are the same as presented in
Figure 5A) SVM.
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Additional File 5: Supplementary Table 3. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the melanoma dataset with the
iRefWeb PPI and the DLDA classifier. The samples are identified by their
Tumour IDs. The order of the samples are the same as presented in
Figure 5A) DLDA.
Additional File 6: Supplementary Table 4. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the ovarian cancer dataset with
the iRefWeb PPI and the RF classifier. The samples are identified by their
Tumour IDs. The order of the samples are the same as presented in
Figure 5B) RF.
Additional File 7: Supplementary Table 5. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the ovarian cancer dataset with
the iRefWeb PPI and the SVM classifier. The samples are identified by
their Tumour IDs. The order of the samples are the same as presented in
Figure 5B) SVM.
Additional File 8: Supplementary Table 6. A numerical representation
of the number of cross-validation rounds (out of 100) in which each
sample is correctly classified when using the ovarian cancer dataset with
the iRefWeb PPI and the DLDA classifier. The samples are identified by
their Tumour IDs. The order of the samples are the same as presented in
Figure 5B) DLDA.
Additional File 9: Supplementary results. Results based on the
MetaCore™ PPI network and comparisons of the MetaCore™ network
with the iRefWeb network and the ovarian cancer dataset with the
melanoma dataset.
Additional File 10: Supplementary Figure 2. Classification error rates
obtained from 100 rounds of 5-fold cross-validation for the melanoma
dataset and MetaCore™ PPI network. The error rates are presented for
the RF classifier, the SVM classifier and the DLDA classifier for the
melanoma dataset and the MetaCore™ PPI network. The numbers within
the parentheses following the method names are the number of
selected features in each cross-validation round.
Additional File 11: Supplementary Figure 3. Class-specific classification
error rates obtained from the average of 100 rounds of 5-fold cross
validation for the melanoma dataset and MetaCore™ PPI network. The
average GP (dotted line) and PP (solid line) error rates for each method
are presented for the RF classifier, the SVM classifier and the DLDA
classifier using the melanoma dataset and the MetaCore™ PPI network.
Additional File 12: Supplementary Figure 4. Stability for the feature
selection methods for the melanoma dataset and MetaCore™ PPI
network. The number of selected features pair-wise in common over the
100 rounds of 5-fold cross-validation (thus over a total of 500 selected
feature lists) for each of the single-gene, gene-set and network methods
based on the MetaCore™ PPI network for the melanoma dataset, with
respect to the number of features selected.
Additional File 13: Supplementary Figure 5. Classification accuracy at
the patient level for the melanoma dataset and the MetaCore™ PPI
network. A black cell corresponds to the patient being classified correctly
in all 100 CV rounds, whereas a white cell corresponds to the patient
being classified correctly in none of the 100 CV rounds for the RF
classifier, the SVM classifier and the DLDA classifier using the MetaCore™
PPI network and the melanoma dataset. The rows are split into non-
grouping methods (first two rows) and grouping methods (last three
rows). The tumor IDs are given on the x-axis, and the average error rate
(taken over the 100 rounds of CV) are provided on the y-axis on the
right-hand side.
Additional File 14: Supplementary Table 7. A numerical
representation of the number of cross-validation rounds (out of 100) in
which each sample is correctly classified when using the melanoma
dataset with the MetaCore™ PPI network and the RF classifier. The
samples are identified by their Tumour IDs. The order of the samples are
the same as presented in Supplementary Figure 5) RF.
Additional File 15: Supplementary Table 8. A numerical
representation of the number of cross-validation rounds (out of 100) in
which each sample is correctly classified when using the melanoma
dataset with the MetaCore™ PPI network and the SVM classifier. The
samples are identified by their Tumour IDs. The order of the samples
are the same as presented in Supplementary Figure 5) SVM.
Additional File 16: Supplementary Table 9. A numerical
representation of the number of cross-validation rounds (out of 100) in
which each sample is correctly classified when using the melanoma
dataset with the MetaCore™ PPI network and the DLDA classifier. The
samples are identified by their Tumour IDs. The order of the samples
are the same as presented in Supplementary Figure 5) DLDA.
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